Experiment 909596

Details

PropertyValue
Pharmacology
Administration routeIV INFUSION
OrganismEmpty organism
CitationANON:. (1990). TAXOL.. 15(1)
Amount utilized
Compound isolated
Disease17 PATIENTS WITH REFRACTORY LEUKEMIA WERE USED IN A PHASE I TRIAL. SIDE EFFECTS INCLUDED SEVERE MUCOSITIS, PERIPHERAL NEUROPATHY, ALOPECIA, MYALGIAS/ARTHRALGIAS, NAUSEA, VOMITING, DIARRHEA AND ACUTE PULMONARY REACTION TO THE VECHICLE CREMOPHOR. MAXIMUM TOLERATED DOSE RECOMMENDED FOR PHASE II TRIAL WAS 390 AND 315 MG/SQ.M.
Dose amountVAR
Number8
Qualitative result.
AnimalHUMAN ADULT
Dose expressionDOSE